Xenetic Biosciences Inc   (XBIO)
Other Ticker:  
Price: $3.9100 $0.30 8.319%
Day's High: $3.9399 Week Perf: 1.69 %
Day's Low: $ 3.60 30 Day Perf: 11.4 %
Volume (M): 4 52 Wk High: $ 5.97
Volume (M$): $ 15 52 Wk Avg: $2.97
Open: $3.60 52 Wk Low: $0.26

 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees -
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 0

Xenetic Biosciences Inc
Xenetic Biosciences Inc is a biopharmaceutical company that focuses on the development of next-generation biologic drugs and technologies. The company uses its proprietary drug development platform, PolyXen, to improve the efficacy, safety, and half-life of therapeutic proteins and peptides.

Xenetic Biosciences has a range of product candidates in various stages of development, including oncology drugs, anemia treatments, and blood coagulation disorders. These products aim to address unmet needs in the market and provide innovative solutions for patients.

The company also collaborates with pharmaceutical partners to develop and commercialize its products, leveraging their expertise and resources. Xenetic Biosciences has a global presence and seeks to expand its product portfolio through strategic partnerships and acquisitions.

Overall, Xenetic Biosciences Inc aims to advance the field of biotechnology by developing novel and transformative therapies that can significantly impact patient health outcomes.

   Company Address: 945 Concord Street Framingham 1701 MA
   Company Phone Number: 778-7720   Stock Exchange / Ticker: NASDAQ XBIO
   XBIO is expected to report next financial results on March 21, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Xenetic Biosciences Inc

Xenetic Biosciences Delivers Impressive Third Quarter Results, Reaching Break-Even Earnings Amidst Challenging Market

Investors Look to the Future as Xenetic Biosciences Reports Break-Even Earnings in Q3 2023

Xenetic Biosciences Inc, a leading biopharmaceutical company, recently announced its financial performance for the third quarter of 2023. Investors were pleased to learn that the company reached a break-even point of $0.00 per share, compared to the same period last year, where earnings were also at $0.00 per share. This marks a significant improvement from the prior financial reporting period when the company reported earnings of $0.00 per share.
Additionally, Xenetic Biosciences Inc reported a remarkable 47.537% increase in revenue, with earnings totaling $0.61 million for the third quarter of 2023, compared to $0.41 million in the same period a year ago. However, there was a slight sequential decrease in revenue by -6.118% from $0.65 million in the previous financial reporting period.

Xenetic Biosciences Inc

Astounding 56.225% Surge in Revenue Propels Xenetic Biosciences Inc to New Heights in Q2 2023

Xenetic Biosciences Inc, a biotechnology company traded on NASDAQ, has recently experienced significant fluctuations in its stock performance. While the stock experienced a decline of -11.53% in the past 7 days, it has seen an impressive year-to-date performance of 1132.79%, indicating overall positive growth. Additionally, the stock is currently trading at a remarkable 235.8% above its 52-week average. Examining the second quarter financial results, we can delve into the implications these figures may have on the company's future prospects.
1. Break-even point:
During the second quarter of 2023, Xenetic Biosciences Inc achieved a break-even point with earnings per share (EPS) of $0.00. This remains consistent with the previous year's performance and indicates stability. Maintaining a break-even point in EPS shows the company's ability to balance its expenses and revenues effectively.

Xenetic Biosciences Inc

Major Pharmaceutical Preparations Company Reports Revenue of $0.6 Million in Q1 20232. Xenetic Biosciences Inc. Struggles Financially, With $6 Million Net Loss and Negative ROA

Xenetic Biosciences Inc. has been struggling financially, reporting a cumulative net loss of $-6 million during the 12 months ending in the first quarter of 2023. This has resulted in a negative return on assets (ROA) of -38.46%, meaning the company has been unable to generate any profits from its assets.
The company's poor financial performance is concerning, especially when compared to other healthcare companies in the sector. Out of 359 other healthcare companies, Xenetic Biosciences Inc. had a lower ROA than all of them. This is a clear indicator that the company is not performing well financially.
Although the overall ranking of the company's ROA has improved in the first quarter of 2023 to 2688 from the total ROA ranking in the fourth quarter of 2022 at 4456, this is not enough to show significant improvement. The fact that they were ranked so low in the first place indicates that the company still has a long way to go.


Xenetic Biosciences Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com